Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 4 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia 2Respiratory Distress Syndrome 1Psoriasis 1Pneumonia 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Diabetes Mellitus, Type 1 1Cytokine Release Syndrome 1Bronchiolitis Obliterans 1Adenocarcinoma 1

Interventions

Etanercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Psoriasis × Etanercept × Clear all
NCT00585650 2023-08-18

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

University of California, Irvine

Phase 1/2 Completed
20 enrolled 5 charts

Psoriasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡